CriticalImidazole antifungal×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)
Updated · Methodology
Mechanism
The liver eliminates most quinidine through the enzyme CYP3A4, and quinidine levels rise with ketoconazole, for example, perhaps because of competition for this enzyme (quinidine label, US Food and Drug Administration, FDA). Miconazole inhibits CYP3A4, and the miconazole oral gel summary of product characteristics (SmPC) calls it a clinically potent inhibitor of this enzyme (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the same SmPC, oral miconazole must not be combined with QT-prolonging drugs that CYP3A4 metabolises, including quinidine, because their higher levels can prolong the QT interval and cause potentially fatal torsade de pointes (AEMPS). Quinidine prolongs the QT interval in a dose-related way, and high blood levels of quinidine raise the risk of torsade de pointes (quinidine FDA label). Patients hold the gel in the mouth and then swallow it. A 60 mg dose of the gel gives peak plasma miconazole levels of 31–49 ng/mL (miconazole oral gel SmPC, AEMPS). Less than 1% of a cream dose is absorbed (miconazole cream SmPC, AEMPS). Each Spanish vaginal ovule contains 100 mg of miconazole with 300 mg of metronidazole. Their SmPC gives data for 1200 mg miconazole ovules: levels more than 100 times lower than after oral or intravenous use (vaginal ovule SmPC, AEMPS).
Symptoms
The main risk is QT prolongation and potentially fatal polymorphic ventricular tachycardia of the torsade de pointes type (miconazole oral gel summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; quinidine label, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. The risk of torsade de pointes rises with a slow heart rate, low potassium, magnesium or calcium and high quinidine levels, but it can also occur without these factors. Besides torsade de pointes, quinidine can cause frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation (quinidine FDA label). Excess quinidine causes vomiting, diarrhoea, tinnitus, high-frequency hearing loss, vertigo, blurred or double vision, photophobia, headache, confusion and delirium. In overdose, the main dangers are ventricular arrhythmias and low blood pressure (quinidine FDA label).
Management
The combination is contraindicated for oral miconazole. The miconazole oral gel summary of product characteristics (SmPC) names quinidine among the QT-prolonging drugs that must not be used with oral miconazole (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Patients hold the gel in the mouth and then swallow it, so the contraindication also applies when it is used for oral or oesophageal candidiasis (miconazole oral gel SmPC, AEMPS). Quinidine is not on the Spanish medicines register. The US quinidine label names neither miconazole nor azole antifungals as a class, but it states that other drugs can change quinidine levels and, without a dose adjustment, lead to toxicity (quinidine label, US Food and Drug Administration, FDA). The miconazole cream and vaginal ovule SmPCs do not mention quinidine. According to them, little miconazole reaches the blood and clinically relevant interactions are rare (miconazole cream and vaginal ovule SmPCs, AEMPS). The SmPC of the vaginal ovules, which combine miconazole with metronidazole, has a separate line: QT prolongation has been reported, particularly when metronidazole was given with QT-prolonging drugs (vaginal ovule SmPC, AEMPS). Use quinidine with extreme care in people with long QT syndrome, a history of torsade de pointes of any cause, or previous marked lengthening of the heart-rate-corrected QT interval (QTc) in response to quinidine or other drugs that prolong repolarisation (quinidine FDA label). As a rule, start quinidine and change its dose, especially in people with heart disease, in a setting with continuous monitoring and resuscitation facilities. If the QRS complex widens to 130% of baseline, QTc reaches 130% of baseline and exceeds 500 ms, P waves disappear, or significant tachycardia, symptomatic bradycardia or hypotension develops, reduce the dose or stop quinidine (quinidine FDA label). In haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and, if possible, correct them promptly (quinidine FDA label, overdosage section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.3 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026, secciones 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Blasgina óvulos vaginales (nº registro 50441), sección 4.5 (2026)– AEMPS, CIMA, nº registro 50441 (Blasgina óvulos vaginales, Almirall), revisión 09/2026, secciones 4.4, 4.5 y 5.2
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage
- AEMPS: Ficha técnica: Miconazol crema (nº registro 50271), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 50271 (Daktarin 20 mg/g crema), revisión 06/2026, secciones 4.4, 4.5 y 5.2 (en el HTML de CIMA siguen al apartado 4.3, sin ancla propia)